All Oncology News

Guilherme Nader-Marta, MD, and Erica L. Mayer, MD, MPH, discusses innovative treatments for HR-positive, HER2-negative metastatic breast cancer.

Scott M. Haake, MD, PhD, discusses how RNAseq-defined clusters could guide treatment selection in metastatic ccRCC, based on data from the OPTIC trial.

Anamorelin plus chemotherapy was well tolerated and potentially associated with efficacy in metastatic urothelial carcinoma.

Treatment with nogapendekin alfa inbakicept plus BCG prolonged duration of complete response compared with BCG alone in patients with BCG-naive NMIBC.

Treatment with an allogeneic CD19-directed CAR natural killer–cell therapy led to an ongoing complete response at 15 months in Waldenstrom lymphoma.

Mayo Clinic’s Department of Radiation Oncology has developed an AI monitoring tool to support clinicians in monitoring for prostate cancer recurrence.

Elena Elimova, MD, discusses findings for zanidatamab chemotherapy with/without tislelizumab in advanced HER2-positive gastroesophageal adenocarcinoma.

ICT01 has received FDA breakthrough therapy designation as frontline therapy for patients with AML who are unfit for induction chemotherapy.

Treatment with pembrolizumab after GI-6207 therapy did not generate therapeutic responses in patients with recurrent/metastatic medullary thyroid cancer.

Nemtabrutinib plus venetoclax showed early activity and manageable safety in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

The AACN's Beacon Award for Excellence has been awarded to Roswell Park Comprehensive Cancer Center's Intensive Care Unit.

The autologous tumor-cell immunotherapy improved OS and RFS vs placebo in patients who achieved a CR after undergoing surgery and frontline chemotherapy.

Teclistamab monotherapy significantly improved PFS and OS vs standard-of-care therapy in relapsed/refractory multiple myeloma as early as the second line.

Yue Wei, PhD, discussed the role of HMAs in platelet response in MDS and the clinical relevance of using a mouse model to investigate this approach.

Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.

SCIB1/iSCIB1+ plus ipilimumab and nivolumab displayed T-cell responses in treatment-naive, unresectable melanoma.

Updated data from the GOBLET trial show pelareorep plus atezolizumab achieved a 29% ORR with durable responses in heavily pretreated SCAC.

Andrea Necchi, MD, dives into the details of the SunRISe-4 trial findings, implications, and ways that utDNA and ctDNA may operate as biomarkers in MIBC.

Mark A. Socinski, MD, and Martin F. Dietrich, MD, PhD, discuss molecular testing methodologies for NSCLC.

Nogapendekin alfa inbakicept plus an immune checkpoint inhibitor generated absolute lymphocyte count increases in non–small cell lung cancer.

The expansion of WVU Medicine hospitals across the state is changing how and where patients, including those with cancer, receive care.

David P. Carbone, MD, PhD, and Niels Reinmuth, MD, PhD, discussed the landscapes of biomarker testing and screening in NSCLC.

Andrew W. Hahn, MD, discusses the efficacy and safety of lenvatinib plus everolimus in metastatic ccRCC after progression on PD-1–directed ICIs

Treatment discontinuation with first-line BTK inhibitors was higher in the real-world setting vs the clinical trial setting among patients with CLL/SLL.

Jessica C. Hassel, MD, discusses the mechanism of action of the IO102-IO103 vaccine and the implications of its efficacy data in melanoma.

Virginia Kaklamani, MD, discusses data from the ELEVATE study of elacestrant as a combination component in ER+/HER2- breast cancer.

A study led by UC San Francisco researchers found that anti-LAG-3/anti-PD-1 combination therapy shows a higher risk of myocarditis vs other ICI treatments.

The FDA has accepted an NDA for pimicotinib in tenosynovial giant cell tumor, supported by data from the phase 3 MANEUVER trial.

A target action date of August 30, 2026, has been set for the FDA's decision regarding the sBLA seeking the approval of ropeginterferon alfa-2b for ET.

LY4170156 was well tolerated and generated promising efficacy data in patients with recurrent, platinum- resistant high-grade serous ovarian cancer.